Passage Bio, Inc. — Form 8-K Summary
Reporting date: December 20, 2023. The filing was submitted under Item 8.01, Other Events, and reports clinical, strategic and pipeline updates. It does not present quarterly or annual financial statements.
Business Context and Program Updates
Passage Bio is a clinical-stage gene therapy company focused on central nervous system disorders. The company provided updates on its global Phase 1/2 upliFT-D trial of PBFT02, an adeno-associated virus-delivered gene therapy for frontotemporal dementia caused by progranulin deficiency, or FTD-GRN.
- The trial is designed to evaluate safety and tolerability over 24 months, followed by 36 months of long-term follow-up.
- The study includes two planned dose-escalation cohorts, with a potential third higher-dose cohort if needed.
- Secondary measures include cerebrospinal fluid and plasma progranulin, neurodegeneration biomarkers and clinical outcomes.
Clinical and Other Key Metrics
- Initial data covered the first three Cohort 1 patients receiving Dose 1.
- Cerebrospinal fluid progranulin increased 3.6 to 6.6 times from baseline at Day 30, with levels of 10.7 to 17.3 ng/mL versus 3.3 to 8.2 ng/mL in healthy adult controls.
- At six months, cerebrospinal fluid progranulin was 27.3 ng/mL in one patient.
- Plasma progranulin remained below healthy-control levels during the available follow-up period.
- Patients 2 and 3, treated under an enhanced steroid regimen, had no serious adverse events, only mild-to-moderate treatment-emergent adverse events, and no clinically significant immune response, hepatotoxicity or safety-related imaging findings.
- Patient 1, treated under the initial lower-immunosuppression protocol, experienced two asymptomatic serious adverse events considered likely consistent with an immune response.
- No evidence of dorsal root ganglion toxicity was observed in nerve conduction studies, and no complications from intra-cisterna magna administration were reported.
Financial Position and Liquidity
The filing does not provide revenue, net income or loss, cash flow, margins, debt, cash balance, liquidity, cash runway or other financial metrics. The filing references management expectations regarding cash runway as forward-looking information but provides no clear value.
Material Changes and Strategic Priorities
- The protocol was amended after Patient 1 to increase immunosuppression for subsequent patients.
- The company intends to treat two additional patients at Dose 1 without a required delay between those patients.
- Passage Bio is prioritizing continued clinical development of PBFT02 for FTD-GRN, expansion into additional adult neurodegenerative diseases and advancement of its preclinical Huntington’s disease program with the University of Pennsylvania’s Gene Therapy Program.
- The company is seeking potential partnerships for its clinical-stage pediatric programs in GM1 gangliosidosis, Krabbe disease and metachromatic leukodystrophy.
Outlook, Risks and Contingencies
- Cohort 2 dosing is expected to begin in the first half of 2024.
- Full six-month Cohort 1 safety and biomarker data are expected in the second half of 2024.
- Twelve-month Cohort 1 follow-up and initial Cohort 2 safety and biomarker data are expected in the first half of 2025.
- The company expects regulatory feedback regarding potential clinical pathways for FTD-C9orf72 and ALS in the second half of 2024 and is exploring preclinical studies in Alzheimer’s disease.
- Potential expansion indications include FTD-C9orf72, ALS and Alzheimer’s disease involving reduced progranulin levels, but these opportunities remain subject to further research and regulatory development.
- Forward-looking statements are subject to risks involving clinical-trial execution, safety and efficacy, regulatory review, manufacturing, partnerships, financing and cash runway. The filing directs investors to the company’s subsequent SEC filings, including its September 30, 2023 Form 10-Q.
Most Important Facts to Verify
- Whether the initial biomarker improvements are sustained and translate into clinical benefit.
- The full safety profile, including the cause and recurrence risk of the serious adverse events observed in Patient 1.
- Timing and results of Cohort 2 dosing and subsequent interim analyses.
- Updated cash balance, operating cash use, financing needs and cash runway, which are not disclosed in this filing.
- Regulatory feedback and the feasibility of expanding PBFT02 into FTD-C9orf72, ALS and Alzheimer’s disease.
- Progress toward partnerships for the pediatric programs and advancement of the Huntington’s disease program.